share_log

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52

Benzinga ·  May 1 05:34

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment